陆永奎, 胡晓桦, 黎福祥, 刘志辉, 谢伟敏, 周文献, 李永强, 谭晓虹, 廖小莉, 廖萍, 黄秉琰. 基因工程腺病毒(H101)瘤内注射联合化疗治疗鼻咽癌的疗效观察[J]. 中国肿瘤临床, 2005, 32(19): 1096-1099.
引用本文: 陆永奎, 胡晓桦, 黎福祥, 刘志辉, 谢伟敏, 周文献, 李永强, 谭晓虹, 廖小莉, 廖萍, 黄秉琰. 基因工程腺病毒(H101)瘤内注射联合化疗治疗鼻咽癌的疗效观察[J]. 中国肿瘤临床, 2005, 32(19): 1096-1099.
shu
Lu Yongkui, Hu Xiaohua, Li Fuxiang, Liu Zhihui, Xie Weimin, Zhou Wenxian, Li Yongqiang, Tan Xiaohong, Liao Xiaoli, Liao Ping, Huang Bingyan. Clinical Observation of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Chemotherapy in Treatment of Nasopharyngeal Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(19): 1096-1099.
Citation: Lu Yongkui, Hu Xiaohua, Li Fuxiang, Liu Zhihui, Xie Weimin, Zhou Wenxian, Li Yongqiang, Tan Xiaohong, Liao Xiaoli, Liao Ping, Huang Bingyan. Clinical Observation of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Chemotherapy in Treatment of Nasopharyngeal Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(19): 1096-1099.
shu

基因工程腺病毒(H101)瘤内注射联合化疗治疗鼻咽癌的疗效观察

Clinical Observation of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Chemotherapy in Treatment of Nasopharyngeal Carcinoma

    摘要
  • 摘要: 目的: 观察瘤内注射基因工程腺病毒(H101)联合化疗治疗鼻咽癌的近期疗效和不良反应。 方法: 符合入选标准的鼻咽癌患者54例,给予H101瘤内注射,每天一次,每次一支(5×1011病毒颗粒/0.5ml),连续5天,同时联合PF方案(DDP20mg/m2静滴,d1～5,5-FU500mg/m2静滴,d1～5)或AF方案(ADM50mg/m2静注d1;5-FU500mg/m2静滴,d1～5)化疗,21天为一周期,所有患者均接受2个周期的治疗。 结果: 在可评价的54例患者中注射病灶的总有效率为77.7%,其中CR10例,PR32例。主要不良反应为注射部位局部疼痛20.4%,非感染性发热40.7%,流感样症状9.3%,未见严重不良事件。 结论: 在全身化疗的同时瘤内注射基因工程腺病毒(H101)对鼻咽癌有明确的治疗作用,不良反应低,易为患者接受。

     

    Abstract: Objective :To evaluate the efficacy and toxicity of intratumoral H101, a E1B-deletedadenovirus, in combination with chemotherapy on patients with nasopharyngeal carcinoma. Methods :A total of 54 patients with nasopharyngeal carcinoma were treated with H101, 5*10 viral particle per day for 5 consecutive days. PF regimen (cisplatin 20mg/mz ivgtt, qd*Sd; 5-fluorouracil 500mg m ivgtt, qd *Sd) or AF remen (adriamycin SOm m2 iv, d 1;5-fluorouracil 500mg/mz ivgtt, qd *Sd) was administered to patients at the same time. Treatment repeated every 3 weeks, and all patients received 2 cycles of chemotherapy. Results :Among 54 evaluable cases, the overall response rate was 77.7%,including 10 cases of CR and 32 cases of PR. Main side effects were injection site pain (20.4%)and fever (40.7%), and influenza- like symptoms (9.3%). Serious adverse events were not found in the course of treatment. Conclusions :The study shows that the combination of genetically E1B-deleted adenovirus (H101) possessed a distinct efficacy in patients with naso-pharyngeal carcinoma, and the toxicities were lower and will tolerated.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回